TY - JOUR
T1 - Discovery of small molecules interacting at lactate dehydrogenases tetrameric interface using a biophysical screening cascade
AU - Thabault, Léopold
AU - Brustenga, Chiara
AU - Savoyen, Perrine
AU - Van Gysel, Mégane
AU - Wouters, Johan
AU - Sonveaux, Pierre
AU - Frédérick, Raphaël
AU - Liberelle, Maxime
N1 - Funding Information:
This work was supported by ERC independent researcher Starting Grant 243188 , TUMETABO, the Belgian Science Policy Office (Belspo; Interuniversity Attraction Pole Grant P7/03), the French Community of Belgium (ARC 14/19–058 and ARC 21/26–115), the Belgian Fonds National de la Recherche Scientifique (F.R.S.-FNRS; Grants 3.4575.11, 2.5025.12, and 31288018), the Belgian Fondation contre le Cancer (Fundamental Research Grant FAF-F/2018/1282), and the Télévie (Grants 7.4507.14, 7.8504.18, and 7.4647.20). P.S. is a Research Director of the F.R.S.-FNRS. L.T. was a Ph.D. Fellow of the F.R.S.-FRNS then a Postdoctoral Researcher of the Belgian Fondation contre le Cancer. Funding sources had no role in study design, data collection and interpretation, or the decision to submit the work for publication. The authors thank the Nuclear and Electron Spin Technology (NEST) platform for providing access to the Bruker Ascend Avance III 600 MHz system.
Funding Information:
This work was supported by ERC independent researcher Starting Grant 243188, TUMETABO, the Belgian Science Policy Office (Belspo; Interuniversity Attraction Pole Grant P7/03), the French Community of Belgium (ARC 14/19?058 and ARC 21/26?115), the Belgian Fonds National de la Recherche Scientifique (F.R.S.-FNRS; Grants 3.4575.11, 2.5025.12, and 31288018), the Belgian Fondation contre le Cancer (Fundamental Research Grant FAF-F/2018/1282), and the T?l?vie (Grants 7.4507.14, 7.8504.18, and 7.4647.20). P.S. is a Research Director of the F.R.S.-FNRS. L.T. was a Ph.D. Fellow of the F.R.S.-FRNS then a Postdoctoral Researcher of the Belgian Fondation contre le Cancer. Funding sources had no role in study design, data collection and interpretation, or the decision to submit the work for publication. The authors thank the Nuclear and Electron Spin Technology (NEST) platform for providing access to the Bruker Ascend Avance III 600 MHz system.
Publisher Copyright:
© 2022 Elsevier Masson SAS
PY - 2022/2/15
Y1 - 2022/2/15
N2 - Lactate dehydrogenases (LDHs) are tetrameric enzymes of therapeutic relevance for cancer therapy due to their important implications in cancer cell metabolism. LDH active site inhibition suffers from different drawbacks due to several features such as high cellular concentration and a shared active site among the dehydrogenase family. Conversely, targeting the LDH oligomeric state is an exciting strategy that could provide a suitable alternative to active-site inhibition. In the present study, we developed a biophysical screening cascade to probe the LDHs tetrameric interface. Using nanoscale differential fluorimetry (nanoDSF) as a primary screening method, we identified a series of hits that destabilize the tetrameric protein. From this primary screening, we validated selected hits using saturation transfer difference nuclear magnetic resonance (STD NMR) and microscale thermophoresis (MST) as a combination of orthogonal biophysical techniques. Finally, we characterized the validated hits and demonstrated that they specifically interact at the tetrameric interface of LDH-1 and LDH-5 and can inhibit the LDH tetramerization process. Overall, this work provides a convenient method for screening ligands at the LDH tetrameric interface and has identified promising hits suitable for further optimization. We believe that this biophysical screening cascade, especially the use of (nano)DSF, could be extended to other homomeric proteins.
AB - Lactate dehydrogenases (LDHs) are tetrameric enzymes of therapeutic relevance for cancer therapy due to their important implications in cancer cell metabolism. LDH active site inhibition suffers from different drawbacks due to several features such as high cellular concentration and a shared active site among the dehydrogenase family. Conversely, targeting the LDH oligomeric state is an exciting strategy that could provide a suitable alternative to active-site inhibition. In the present study, we developed a biophysical screening cascade to probe the LDHs tetrameric interface. Using nanoscale differential fluorimetry (nanoDSF) as a primary screening method, we identified a series of hits that destabilize the tetrameric protein. From this primary screening, we validated selected hits using saturation transfer difference nuclear magnetic resonance (STD NMR) and microscale thermophoresis (MST) as a combination of orthogonal biophysical techniques. Finally, we characterized the validated hits and demonstrated that they specifically interact at the tetrameric interface of LDH-1 and LDH-5 and can inhibit the LDH tetramerization process. Overall, this work provides a convenient method for screening ligands at the LDH tetrameric interface and has identified promising hits suitable for further optimization. We believe that this biophysical screening cascade, especially the use of (nano)DSF, could be extended to other homomeric proteins.
KW - Biophysics
KW - Cancer
KW - Drug screening
KW - Lactate dehydrogenases
KW - MicroScale thermophoresis (MST)
KW - Nanoscale differential fluorimetry (NanoDSF)
KW - Nuclear magnetic resonance (NMR)
KW - Oligomerization
KW - Protein-protein interaction
UR - http://www.scopus.com/inward/record.url?scp=85123193224&partnerID=8YFLogxK
U2 - 10.1016/j.ejmech.2022.114102
DO - 10.1016/j.ejmech.2022.114102
M3 - Article
C2 - 35074589
AN - SCOPUS:85123193224
SN - 0223-5234
VL - 230
JO - European Journal of Medicinal Chemistry
JF - European Journal of Medicinal Chemistry
M1 - 114102
ER -